Cancer cell progression and chemoimmunotherapy - Dual effects in the induction of resistance to therapy

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 465-471

  Hamuro, J ^a   Kikuchi, T ^a   Takatsuki, F ^a   Suzuki, M ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Chemoimmunotherapy; Interleukin 2; Lentinan; Prostaglandin; Tumour progression

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; INTERLEUKIN 2; LENTINAN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER REGRESSION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; FIBROSARCOMA; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPH NODE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR GROWTH;

EID: 0030041910     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.82     Document Type: Article

References (38)

1. BALCH CM, DOUGHERTY PA, CLOUD GA AND TILDEN AB. (1984). Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery, 95, 71-77.
2. BRADLY G, JURANKA P AND LING V. (1988). Mechanisms of multidrug resistance. Biochim. Biophys. Acta, 948, 87-128.
3. CEUPPENS J AND GOODWIN J. (1981). Prostaglandins and the immune response to cancer (review). Anticancer Res., 1, 71-78.
4. CHANG KC AND LOEB LA. (1993). Genomic instability and tumour progression: mechanistic considerations. Adv. Cancer Res., 60, 121-156.
5. CHEIFETZ S, WEATHERBEE JA, TSANG ML, ANDERSON JK, MOLE JE, LUCAS R AND MASSAGUE J. (1987). The transforming growth factor β system, a complex pattern of cross-reactive ligands and receptors. Cell, 48, 409-415.
6. CHIHARA G, HAMURO J, MAEDA YY, ARAI Y AND FUKUOKA F. (1969). Fractionation and purification of the polysaccharides with marked anti-tumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res., 30, 2776-2781.
7. DOHERTY PC, KNOWLES BB AND WETTSTEIN PJ. (1984). Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv. Cancer Res., 42, 1-65.
8. GOLDIE JH AND COLDMAN AJ. (1979). A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep., 63, 1727-1733.
9. GOTTESMAN MM. (1988). The multidrug transporter, a double-edged sword. J. Biol. Chem., 263, 12163-12166.
10. HAMURO J AND CHIHARA G. (1985). Lentinan, a T-cell-oriented immunopotentiator: its experimental and clinical applications and possible mechanisms of immune modulation. In Immune Modulation Agents and their Mechanisms. Fenicle RL (ed) pp. 409-437. Dekker.: New York.
11. HUNTER T. (1991). Cooperation between oncogenes. Cell, 64, 249-270.
12. IMAMURA F, HORAI T, MUKAI M, SHINKAI K AND AKEDO H. (1990). Potentiation of invasive capacity of rat ascites hepatoma cells by adriamycin. Cancer Res., 50, 2018-2021.
13. JOHNSON JP, RIETHMULLER G AND SCHIRRMACHER V. (1989). Tumor immunology: Paul Ehrlich heritage. Immunol. Today, 10, S35-S37.
14. KEHRL JH, WAKEFIELD LM, ROBERTS AB, JAKOWLEW S, ALVAREZ-MON M, DERYNCK R, SPORN MB AND FAUCI AS. (1986). Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med., 163, 1037-1050.
15. KRAMER RA, ZAKHER J AND KIM J. (1988). Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science, 241, 694-697.
16. KRAUSE DS AND DEUTSCH C. (1991). Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: expression of both p55 and p75 subunits is affected. J. Immunol., 146, 2285-2294.
17. + T cell function. Jpn. J. Cancer Res., 84, 315-325.
18. MCMILLAN TJ AND HART IR. (1987). Can cancer chemotherapy enhance the malignant behavior of tumours? Cancer Metastasis Rev., 6, 503-520.
19. MAHAN M, MEUNIER J, NEWBY M AND YOUNG MR. (1985). Prostaglandin E2 production by EL 4 leukemia cells from C57BL/ 6 mice: mechanism for tumor dissemination. J. Natl Cancer Inst., 74, 191-195.
20. MITCHELL MS. (1992). Chemotherapy in combination with biomodulation: A 5-year experience with cyclophosphamide and interleukin-2. Semin. Oncol., 19, 80-87.
21. MOSMANN T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
22. OKADA F, HOSOKAWA M, HASEGAWA J, ISHIKAWA M, CHIBA I, NAKAMURA Y AND KOBAYASHI H. (1990). Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2. Cancer Immunol. Immunother., 31, 358-364.
23. OKADA F, HOSOKAWA M, HAMADA J-I, HASEGAWA J, KATO M, MIZUTANI M, REN J, TAKEICHI N AND KOBAYASHI H. (1992). Malignant progression of a mouse fibrosarcoma by host cells reactive to a foreign body (gelatin sponge). Br. J. Cancer, 66, 635-639.
24. OKADA F, HOSOKAWA M, HASEGAWA J, KURAMITSU Y, NAKAI L, LAO H, KOBAYASHI H AND TAKEICHI N. (1994). Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells. Br. J. Cancer, 70, 233-238.
25. PACIUCCI PA, HOLLAND JF, RYDER JS, KONEFAL RG, BEKESI GJ, ODCHIMAR R AND GORDON R, (1989). Immunotherapy with interleukin-2 by constant infusion with and without adoptive transfer and weekly doxorubicin. Cancer Treat. Rev., 16, 67-81.
26. PARHAR RS AND LALA PK. (1987). Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2. J. Exp. Med., 165, 14-28.
27. PHIPPS RP, STEIN SH AND ROPER RL. (1991). A new view of prostaglandin E regulation of the immune response. Immunol. Today, 12, 349-352.
28. RAPPAPORT RS AND DODGE GR. (1982). Prostaglandin E inhibits the production of human interleukin 2. J. Exp. Med., 155, 943-948.
29. SATOH T, MATSUI H, SHIBAHARA S, KOBAYASHI T, MORINAGA Y, KASHIMA N, YAMASAKI S, HAMURO J AND TANIGUCHI T. (1987). New approaches for the high-level expression of human interleukin-2 cDNA in Escherichia coli. J. Biochem., 101, 525-534.
30. SCHIMKE RT. (1984). Gene amplification, drug resistance, and cancer. Cancer Res., 44, 1735-1742.
31. SUZUKI M, TAKATSUKI F, MAEDA YY, HAMUROA J AND CHIHARA G. (1994). Anti-tumor and immunological activity of lentinan in comparison with LPS. Int. J. Immunopharmacol., 16, 462-468.
32. TADA T, OHZEKI S, UTSUMI K, TAKIUCHI H, MURAMATSU M, LI X-F, SHIMIZU J, FUJIWARA H AND HAMAOKA T. (1991). Transforming growth factor β-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol., 146, 1077-1082.
33. TAGUCHI T, FURUE H, KIMURA T, KONDOH T, HATTORI T, ITO I AND OGAWA N. (1985). Endpoint result of a randomized controlled study on the treatment of gastro-intestinal cancer with a combination of lentinan and chemotherapeutic agents. In Rationale of Biological Response Modifiers in Cancer Treatment. Tsubura E, Urushizaki I and Aoki T (eds) pp.151-166. Excerpta Medica: Amsterdam.
34. TANAKA Y AND TEVETHIA SS. (1988). In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J. Immunol., 140, 4348-4354.
35. TURVER CJ AND BROWN RC. (1987). The role of catalytic iron in asbestos induced lipid peroxidation and DNA-strand breakage in C3H10T1/2 cells. Br. J. Cancer, 56, 133-136.
36. VOGELSTEIN B, FEARON ER, KERN SE, HAMILTON SR, PREISINGER AC, NAKAMURA Y AND WHITER. (1989). Allelotype of colorectal carcinomas. Science, 244, 207-211.
37. WARD JF. (1988). DNA damage produced by ionizing radiation in mammalian cells: Identities, mechanisms of formation and repairability. Prog. Nucleic Acid Res., 35, 95-125.
38. ZIMMARMAN R AND CERUTTI PA. (1984). Active oxygen acts as a promotor of transformation in mouse embryo C3H/10T1/2C18 fibroblast. Proc. Natl Acad. Sci. USA, 81, 2085-2087.